Coverage
Filings
Danish biosolutions company Novonesis on Thursday raised its full-year sales forecast after reporting strong growth for the first nine months of the year, citing a robust performance across its markets.
Novonesis on Wednesday laid out new long-term financial targets, aiming to accelerate sales growth and expand profit margins through 2030 as part of its new ‘GROW’ strategy.
Novonesis has successfully completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, the company announced.
| 22 Apr 2025 |
| Transactions under Novonesis' share buyback program | 14 Apr 2025 |
| Transactions under Novonesis' share buyback program | 7 Apr 2025 |
| Resolutions from the Annual General Meeting 2025 | 3 Apr 2025 |
| Transactions under Novonesis' share buyback program | 31 Mar 2025 |